FOLFOX-4 Treatment for Advanced Gastric Cancer
Author Information
Author(s): De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema M R, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco A R
Primary Institution: Second University of Naples School of Medicine
Hypothesis
The study aims to assess the toxicity and clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil and folinic acid in patients with advanced gastric cancer.
Conclusion
FOLFOX-4 is an active and well-tolerated chemotherapy regimen for advanced gastric cancer, showing a response rate of 38% and a median overall survival of 11.2 months.
Supporting Evidence
- Four complete responses and 19 partial responses were observed, leading to an overall response rate of 38%.
- Stable disease was observed in 36% of patients.
- The median time to progression was 7.1 months.
- The median overall survival was 11.2 months.
- Grade 3 and 4 hematologic toxicities were observed in 36% and 10% of patients, respectively.
Takeaway
Doctors tested a new medicine combination to help people with a serious stomach cancer, and it worked pretty well for many of them.
Methodology
Patients received oxaliplatin, folinic acid, and 5-fluorouracil every two weeks, and their responses and toxicities were assessed.
Limitations
The study was limited to previously untreated patients and may not represent all advanced gastric cancer cases.
Participant Demographics
{"median_age":64,"sex_distribution":{"male":62,"female":38},"performance_status":{"0":15,"1":64,"2":21},"metastatic_disease":92}
Statistical Information
P-Value
0.0026
Confidence Interval
{"overall_response_rate":"95% CI, 25.8–50.2","median_time_to_progression":"95% CI, 5.6–8.7","median_overall_survival":"95% CI, 9.66–14.39"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website